Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 10/2012

01-10-2012 | Research Article

Outcomes and prognostic factors of conformal radiotherapy versus intensity-modulated radiotherapy for nasopharyngeal carcinoma

Authors: Wei Lu Kuang, Qin Zhou, Liang Fang Shen

Published in: Clinical and Translational Oncology | Issue 10/2012

Login to get access

Abstract

Introduction

This study retrospectively compared outcomes and prognostic factors of nasopharyngeal carcinoma (NPC) treated with conformal radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT).

Materials and methods

The treatment records of 182 patients treated with IMRT and 198 patients treated with CRT from April 2005 to December 2007 in our hospital were reviewed. The clinical characteristics, treatment outcomes (including survival analysis and acute and late toxicity), and prognostic factors of the two groups were compared.

Results

The 4-year local–regional control (LRC), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) of the IMRT and CRT groups were 93.6 and 85.3 %, 79.1 and 73.6 %, 74.7 and 65.0 %, and 83.5 and 72.1 %, respectively. The acute radiation dermatitis and xerostomia of the two groups were significantly different (P < 0.05). In the IMRT group, OS between different T stages could not be well separated. Multivariate analysis revealed that, in the CRT group, the clinical stage and T and N stages were significant prognostic factors for OS, DMFS, and DFS and that T stage was a significant prognostic factor for LRC. In the IMRT group, T and N stages had no predictive value for outcomes.

Conclusions

Compared with CRT, IMRT has a better prognosis and less adverse effects. For IMRT, T stage was not a significant prognostic factor for LRC, DMFS, DFS, or OS. An effective treatment strategy is needed for distant control. With the increasing use of IMRT and continued modulation of treatment strategies for NPC, the current staging system faces great challenges.
Literature
1.
Jia WH, Huang QH, Liao J, Ye W, Shuqart YY, Liu Q et al (2006) Trends in incidence and mortality of nasopharyngeal carcinoma over a 20–25 year period (1978/1983–2002) in Sihui and Cangwu counties in Southern China. BMC Cancer 6:178–186PubMedCrossRef
2.
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRef
3.
Zhang Y, Lin ZA, Pan JJ, Zheng Z, Yang L, Lin SJ et al (2009) Concurrent control study of different radiotherapy for primary nasopharyngeal carcinoma: intensity-modulated radiotherapy versus conventional radiotherapy. Chin J Cancer 28(11):1143–1148CrossRef
4.
Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH et al (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66(4):981–991PubMedCrossRef
5.
Kwong DL, Pow EH, Sham JS, McMillan AS, Leung WK, Chua DT et al (2004) Intensity-modulated radiotherapy for early stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer 101(7):1584–1593PubMedCrossRef
6.
Lee N, Xia P, Quivey JM, Sultanem K, Poon L, Akazawa C et al (2002) Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53(1):12–22PubMedCrossRef
7.
Butler EB, Teh BS, Grant WH 3rd, Uhl BM, Kuppersmith RB, Chiu JK et al (1999) Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radtat Oncol Biol Phys 45(1):21–32CrossRef
8.
Mendenhall WM, Amdur RJ, Palta JR (2006) Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 24(17):2618–2623PubMedCrossRef
9.
Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, Kwan WH et al (2004) Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 60(5):1440–1450PubMedCrossRef
10.
Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ (2006) Intensity-modulated radiotherapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 64(1):57–62PubMedCrossRef
11.
Yu KH, Teo PM, Lee WY, Leung SF, Choi PH, Johnson PJ (1994) Patterns of early treatment failure in non-metastatic nasopharyngeal carcinoma: a study based on CT scanning. Clin Oncol (R Coll Radiol) 6(3):167–171CrossRef
12.
Li JX, Lu TX, Huang Y, Han F, Chen CY, Xiao WW (2010) Clinical features of 337 patients with recurrent nasopharyngeal carcinoma. Chin J Cancer 29(1):82–86PubMedCrossRef
13.
Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT et al (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1,753 patients. Int J Radiat Oncol Biol Phys 64(1):47–56PubMedCrossRef
14.
Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ et al (2004) The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 22(22):4604–4612PubMedCrossRef
15.
Huncharek M, Kupelnick B (2002) Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 25(3):219–223PubMedCrossRef
16.
Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L et al (2005) Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23(28):6966–6975PubMedCrossRef
17.
Lu X, Guo X, Hong MH, Chen QY, Zeng Q, Xiang YQ (2010) Comparison of the short-term efficacy of two inductive chemotherapy regimens for locally advanced nasopharyngeal carcinoma: docetaxal plus carboplatin versus 5-fluorouracil plus carboplatin. Chin J Cancer 29(2):140–144PubMedCrossRef
18.
Xie FY, Qi SN, Hu WH, Zou GR, Peng M, Li JS (2007) Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma. Ai Zheng 26(8):880–884PubMed
19.
Huang PY, Mai HQ, Luo DH, Qiu F, Li NW, Xiang YQ et al (2009) Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Ai Zheng 28(10):1033–1042PubMedCrossRef
20.
Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK et al (2009) Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 27:242–249PubMedCrossRef
21.
Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY et al (2002) A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 52(5):1238–1244PubMedCrossRef
22.
Liu MZ, Tang LL, Zong JF, Huang Y, Sun Y, Mao YP et al (2008) Evaluation of sixth edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement. Int J Radiat Oncol Biol Phys 70(4):1115–1123PubMedCrossRef
23.
Mao YP, Xie FY, Liu LZ, Sun Y, Li L, Tang LL et al (2009) Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys 73(5):1326–1334PubMedCrossRef
24.
Han L, Lin SJ, Pan JJ, Chen CB, Zhang Y, Zhang XC et al (2010) Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Chin J Cancer 29(2):145–150PubMedCrossRef
25.
Lin S, Lu JJ, Han L, Chen Q, Pan J (2010) Sequential chemotherapy and intensity-modulated radiotherapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer 10:39PubMedCrossRef
26.
Zhang Y, Lin J, Zhou W, Tang J, Liao Y (2009) Dosimetric verification and clinical efficacy of intensity modulated radiotherapy in nasopharyngeal carcinoma. Zhong Nan Da Xue Xue Bao Yi Xue Ban 34(9):879–885PubMed
Metadata
Title
Outcomes and prognostic factors of conformal radiotherapy versus intensity-modulated radiotherapy for nasopharyngeal carcinoma
Authors
Wei Lu Kuang
Qin Zhou
Liang Fang Shen
Publication date
01-10-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 10/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0864-5

Other articles of this Issue 10/2012

Clinical and Translational Oncology 10/2012 Go to the issue

Research Article

Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells

Educational Series – Red Series*

Surveillance of resected non-small cell lung cancer

Research Article

Intensity modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) in a patient with left breast cancer and pectus excavatum

Editorial

Cost-effectiveness, cancer burden and financial crisis: a perfect storm

Research Article

Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA

Research Article

The SGBS cell strain as a model for the in vitro study of obesity and cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits